Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

360
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
360
Riboswitches01:56

Riboswitches

8.7K
Riboswitches are non-coding mRNA domains that regulate the transcription and translation of downstream genes without the help of proteins. Riboswitches bind directly to a metabolite and can form unique stem-loop or hairpin structures in response to the amount of the metabolite present. They have two distinct regions – a metabolite-binding aptamer and an expression platform.
The aptamer has high specificity for a particular metabolite which allows riboswitches to specifically regulate...
8.7K
Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Analysis of Meat Quality and Muscle Transcriptome between Landrace and Jeju Native Pig.

Food science of animal resources·2026
Same author

Glutamate excreted by LepR⁺ BM-MSCs mitigates alcohol-associated liver disease by promoting IL-1R2⁺ monocyte migration.

Clinical and molecular hepatology·2026
Same author

Polyhydroxyalkanoate-Based Microparticles for Enhanced Photostability and Controlled Release of Pyraclostrobin.

Polymers·2026
Same author

Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease.

Annals of the rheumatic diseases·2026
Same author

Phenylalanyl-tRNA synthetase FARS-1/FARSA balances longevity and immunity by downregulating endogenous mitochondrial double-stranded RNAs.

Molecular cell·2026
Same author

Self-amplifying CRISPR-based one-pot ultrasensitive testing for rapid SARS-CoV-2 and its variant detection.

Biosensors & bioelectronics·2026
Same journal

Engineering graphene oxide interfaces for electrochemical biosensing of biomolecules, cells, and organoids.

Nano convergence·2026
Same journal

Laser-irradiated coffee waste: a path to eco-friendly anode materials for lithium-ion batteries.

Nano convergence·2026
Same journal

Synergistic photothermal and magnetothermal heat generation with Sc-doped iron oxide nanoflakes: a platform for potential bimodal tumor therapy.

Nano convergence·2026
Same journal

2D MoS<sub>2</sub>-conformal 3D-printed platform for dual-phototherapy and bone regeneration.

Nano convergence·2026
Same journal

High-throughput discovery of Li<sub>3</sub>Sc<sub>2</sub>(PO<sub>4</sub>)<sub>3</sub> as a protective coating for stabilizing mid-Ni NCM interfaces in all-solid-state batteries.

Nano convergence·2026
Same journal

Optimization strategies for crystal orientation in antimony-based chalcogenide thin-film solar cells.

Nano convergence·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Self-modulating therapeutic platform using engineered miRNA-responsive oligonucleotides.

Doyeong Ku1, Hansol Kim1, JinA Lim1

  • 1Department of Chemical and Biomolecular Engineering (BK 21+ Program), Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea.

Nano Convergence
|June 30, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed a novel miRNA-trigger oligonucleotide to selectively downregulate disease-associated microRNAs (miRNAs). This approach targets anti-apoptotic genes, inducing cancer cell apoptosis and reducing tumor volume in vivo, establishing a new therapeutic platform.

Keywords:
Apoptosis inductionBCL-xL geneGene regulationOligonucleotide therapymiRNAs

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.8K
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.8K

Related Experiment Videos

Last Updated: Sep 17, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

7.8K
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

12.8K

Area of Science:

  • Molecular Biology
  • Oligonucleotide Therapeutics
  • Cancer Research

Background:

  • MicroRNAs (miRNAs) are crucial in post-transcriptional gene regulation and implicated in various diseases.
  • miRNAs are recognized as potential biomarkers and therapeutic targets due to their role in disease pathogenesis.
  • Current therapeutic strategies targeting miRNAs are limited.

Purpose of the Study:

  • To introduce a novel oligonucleotide probe, termed miRNA-trigger, for selective miRNA-mediated gene downregulation.
  • To engineer miRNA-triggers to target specific disease-associated miRNAs and their downstream effects.
  • To evaluate the therapeutic potential of miRNA-triggers in cancer treatment.

Main Methods:

  • Design and synthesis of miRNA-trigger oligonucleotides.
  • Engineering miRNA-triggers to specifically bind and hijack target miRNAs.
  • Demonstration of selective mRNA downregulation and apoptosis induction in cancer cells.
  • In vivo validation of therapeutic efficacy in a xenograft mouse model.

Main Results:

  • The developed miRNA-trigger selectively downregulated target mRNAs by hijacking specific miRNAs.
  • Engineered miRNA-triggers induced apoptosis in breast cancer cells overexpressing specific miRNAs.
  • In vivo administration of miRNA-triggers significantly reduced tumor volume in xenograft mice.
  • The approach demonstrated successful therapeutic efficacy and tumor reduction.

Conclusions:

  • miRNA-triggers represent a novel platform for oligonucleotide therapy by redirecting disease-associated miRNAs.
  • This technology enables targeted gene silencing through miRNA modulation.
  • The findings support the potential of miRNA-triggers as a new therapeutic strategy for miRNA-related diseases, particularly cancer.